Gender

News
September 2, 2019

Women at high risk for HIV infection can use any form of reversible hormonal contraception without any restrictions, including progestogen-only injectables, implants, and intrauterine devices (IUDs), the World Health Organization (WHO) said.

Blog
August 27, 2019

“We know that life-changing HIV prevention solutions are available, but it’s critical to think strategically about how an innovation like PrEP is meaningful to our priority users.

Resource
August 27, 2019

Oral pre-exposure prophylaxis (PrEP) is a new HIV prevention method that offers more than 90 percent protection when taken correctly.

Resource
August 26, 2019

Background: Women account for 56% of new HIV infections in sub-Saharan Africa. Multipurpose Prevention Technologies (MPTs) are promising interventions because they combine HIV prevention with a less stigmatizing indication, such as pregnancy.

Resource
July 30, 2019

mothers2mothers (m2m) is an African NGO working towards the Global Goals of ensuring good health for all and ending the AIDS epidemic by 2030.

Resource
July 16, 2019
Our 9th Research Digest assembles 87 abstracts published from May through June 2019 that feature evidence from Botswana (6), Eswatini/Swaziland (2), Malawi (12), Mozambique (4), South Africa (46), Tanzania (4), Zambia (7) and Zimbabwe (17).
Resource
June 28, 2019
This analysis offers a wide range of scenarios given the considerable uncertainty over ring uptake, consistency of use, and effectiveness, as well as HIV testing, prevention, and treatment use over the next two decades. This could help inform donors and implementers as they decide where to allocate resources in order to maximize the impact of the dapivirine ring in light of funding and implementation constraints.
Blog
June 26, 2019

South Africa’s health data demonstrate that young men are less likely to test for HIV and less likely to start treatment when diagnosed as HIV-positive. Young men living with HIV often transmit the virus to younger female partners, contributing to an inter-generational cycle of transmission.

Resource
June 26, 2019
ARV-based pre-exposure prophylaxis (PrEP) has the potential to avert many new HIV infections, yet little is known about how to reach women at high risk for HIV infection and motivate them to initiate PrEP. Clinical trials have succeeded in recruiting at-risk participants, evidenced by control arm HIV incidence ≥3% (defined by the World Health Organization as “substantial risk”). We examined experiences from HIV prevention trials to document recruitment strategies and identify practical, potentially effective strategies for reaching women in real-world PrEP delivery.
News
June 26, 2019
Results of a pivotal clinical trial among 7,829 women ages 16-35 in East and Southern Africa provide important evidence to help inform women’s choices for contraception and HIV prevention. The Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study found no substantial difference in HIV risk among women using the three methods of contraception in the study – the copper-releasing intrauterine device (Cu-IUD), a levonorgestrel (LNG) implant (Jadelle) and depot medroxyprogesterone acetate-intramuscular (DMPA-IM), also known as Depo-Provera.